Obesity: The Next Investment Driver

As the U.S. gets fatter, so might your wallet..

Investors worldwide are looking at Obesity as one of the maga investment drivers. Obesity cost US $147 Billion. 

Obesity once considered as a medical condition, in the last decade has become one of the biggest health problem facing all the developed countries. Countries like India, China, Brazil are seeing unprecedented obesity rates. Urban India has seen an 14% obesity in tier 1 and 2 cities. China has seen a 40% obesity rate in children, the primary reason is the new found wealth and one child policy which has translated into over pampered kids. 

Individual investors are looking at US to invest in obesity and related technologies. Early stage companies are raising capital from individual investors who clearly believe that investing in obesity is a long term investment. Companies like the lapband technology is so popular all over the world, it is reversible technology that can provide over 45% excess weight loss. This company once was sold to Allergan for over $1.2 B. 

Venture Capitalist saw slowing down of LPs investing in their funds during the 2008-2011 downturn. VCs focused on investments that are later stage or ones that were throw away deals to increase their portfolio. This would make them look good!.

So, what happened to VCs and obesity technologies 2001-2010. Some VCs were first to jump in and experimented their investments on projects while industry was still in learning mode. Today in 2012 the technology companies have become mature, the market is mature, the users mainly the bariatric surgeons have understood how to treat obesity. FDA is now approving drugs and devices to treat obesity. So now, the VCs are looking at obesity as an opportunity. However, VCs are now competing with individual investor community and wealth mangers to invest in next generation technologies in the obesity space. 

Obesity technologies in the US are very limited. Most of them are located in California. The 10 main players in the obesity space mainly Allergan, GI dynamics, Reshape Medical , Obelon, Onciomed, Valentx, J&J, Coviden, Vibrynt Medical and Cavu Medical.

Allergan, Reshape, Onciomed and Obelon are located in SoCal.

Recently, Reshape and Obelon raised their capital . 

Onciomed has announced that it is raising capital for its novel approach to treatment of obesity and diabetes. They got a second patent for their technology Nov 2012.

 Vybrint, Cavu and Vallentx are in the SV and Santa Barbara area. 

J&J and GI Dynamics is located on the East Coast.

In 2011 Bill Hawkins spoke at the Obesity Innovation Summit in Cleavland Clinic in Ohio and mentioned Medtronic is looking at innovations to treat obesity and metabolic technologies.

Big PE players are looking at obesity as an investment opportunities. Companies that have surgical products are looking at innovative medical devices to add them to their portfolio of products or create a brand new franchise.